Heron Therapeutics Inc

At Heron, we understand what is at stake for patients, their caregivers, and families, which is why we are laser-focused on providing solutions that can address unmet medical needs so they can spend more time doing the things that matter with the people who matter.

Our advanced science, patented technologies, and innovative approach to drug discovery and development has allowed us to create and commercialize a portfolio of products that aim to advance the standard of care for acute care and oncology patients. SUSTOL® for Chemotherapy-Induced Nausea and Vomiting Prevention (CINV):
U.S. FDA approved as a subcutaneous injection. CINVANTI® for CINV:
U.S. FDA approved as both a 30-minute intravenous (IV) infusion and a 2-minute IV injection. ZYNRELEF® for Postoperative Pain Management:
Approved in the U.S., Canada and 31 European Countries. APONVIE™ for Postoperative Nausea and Vomiting (PONV):
U.S. FDA approved as a 30-second IV injection of aprepitant for PONV. HTX-034 for Postoperative Pain Management

Phase 2 clinical study ongoing for postoperative pain via local application into the surgical site.